urocotin 2
TRANSCRIPT
Date of download: 11/6/2013
Copyright © The American College of Cardiology. All rights reserved.
From: Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy)
JCHF. 2013;1(5):433-441. doi:10.1016/j.jchf.2013.07.003
Recruitment and Treatment Allocation Flow Diagram
RHC = right heart catheterization.
Figure Legend:
Date of download: 11/6/2013
Copyright © The American College of Cardiology. All rights reserved.
From: Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy)
JCHF. 2013;1(5):433-441. doi:10.1016/j.jchf.2013.07.003
Hemodynamic Responses
Mean ± SEM of hemodynamic effects during and after 4-h infusions (shaded in gray) of placebo (open circles) or urocortin-2 (Ucn2) (solid circles). *p < 0.05, **p < 0.01, and †p < 0.001 indicate significant time-by-treatment interaction in the specific time phase.
Figure Legend:
Date of download: 11/6/2013
Copyright © The American College of Cardiology. All rights reserved.
From: Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy)
JCHF. 2013;1(5):433-441. doi:10.1016/j.jchf.2013.07.003
Pulmonary Pressures, Cardiac Output, and Calculated Total Peripheral Resistance Responses
Right heart catheter parameters (mean ± SEM) during and after 4-h infusions (shaded in gray) of placebo (open circles) or urocortin-2 (solid circles). *p < 0.05 and †p < 0.001 indicate significant time-by-treatment interaction in the specific time phase. cTPR = calculated total peripheral resistance; PAP = pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure; RA = right atrial.
Figure Legend:
Date of download: 11/6/2013
Copyright © The American College of Cardiology. All rights reserved.
From: Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy)
JCHF. 2013;1(5):433-441. doi:10.1016/j.jchf.2013.07.003
Renal Responses
(Left panels) Mean ± SEM of renal responses during and after 4-h infusions of placebo (open bars) or urocortin-2 (Ucn2) (solid bars). CrCL = creatinine clearance. (Right panels) Renal responses to placebo without additional furosemide (Fru−) (open bars) and with additional furosemide (Fru+) (light gray bars), and Ucn2 Fru− (solid bars) and Ucn2 Fru+ (dark gray bars) in +4 h to +12 h.
Figure Legend:
Date of download: 11/6/2013
Copyright © The American College of Cardiology. All rights reserved.
From: Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy)
JCHF. 2013;1(5):433-441. doi:10.1016/j.jchf.2013.07.003
Responses of Ucn-2, PRA, AngII, Aldosterone, and Ucn-1
Mean ± 95% confidence interval of plasma aldosterone, angiotensin-II (AngII), plasma renin activity (PRA), urocortin-2 (Ucn2), and urocortin-1 (Ucn1) during and after 4-h infusions (shaded in gray) of placebo (open circles) or Ucn2 (solid circles). †p < 0.001 indicates significant time-by-treatment interaction in the specific time phase.
Figure Legend:
Date of download: 11/6/2013
Copyright © The American College of Cardiology. All rights reserved.
From: Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy)
JCHF. 2013;1(5):433-441. doi:10.1016/j.jchf.2013.07.003
Responses of Natriuretic Peptides, ET-1, and Cortisol
Mean ± 95% confidence interval of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cortisol, endothelin-1 (ET-1), and N-terminal pro-brain natriuretic peptide (NT-proBNP) during and after 4-h infusions (shaded in gray) of placebo (open circles) or urocortin (Ucn2) (solid circles). *p < 0.05 and **p < 0.01 indicate significant time-by-treatment interaction in the specific time phase.
Figure Legend: